in a statement, gilead said...s not the most expensive drug by any means across the nhs. why pick on people with hep c? that's the only bit i am railing against the nhs for doing, is picking on people with hepatitis c and saying you're second class citizens. everybody else gets the drugs that nice say they can get, but not you guys. why? is it because it is associated with drug use? last year, the hepatitis c trust made the unusual decision to take nhs england to the high court, to try and get that cap lifted. the charity lost, but it was unclear at the time how its case was funded. the judge suggested it may have been the drugs industry, which had a lot to gain financially, that was really behind it. that's something the boss of the hepatitis c trust strongly denies. you can categorically tell us that there was no drug industry funding that went into the court case, this was supporting... categorically. we we re we were doing it for patients. it might not have taken money for the court case, but we have looked int

>> the most important one is gilead. you're talking a massive company trading $67 this is a company that was 120. i am not buying. i made a mistake a couple of weeks ago. i don't know if anyone else would buy it. >> i've got to get to the european close. seema mody has it for us. >> hey, scott, european stocks holding on, this as we kick off what will be a very busy week. we have plans for a second scottish ref rehn dense to lead the uk. more on that in just a second. n they have a test coming up. that will be a test of this popular sweeping across europe. let's talk about the scottish vote. it would allow scott lands to negotiate its own trade deals with the european union. strad jits across the board say the referendum is a long-term negative. they're forecasting a 6% drop from this these lerlts. 60% of sales made those sales on the outside. >> thee ma, thanks is mump. >> pete, sorry i had to interrupt you before. but whau have vow. >> no. i appreciate everything being brat up. growing up in a family where i had a surg

. >> part of the lack of movement was that gilead had a good day today. it was up .75 today. >> the it should have been more than it was. i still think ibb is broken to the upside. a couple more days like today we have to ree-virginia wait. given the circumstances, it traded all right. >> what dwoud the other inhibitor companies? >> i think they're okay. >> the data is better. i prefer to own amgen and i think it will continue to work. the bulldog sentiment going into this event had the stock up skyrocketing. so pulling back makes sense. i think long term for holders is a name you want to own. >> a tough week for snap has it heading back to $17 a share. the traders tell you how much lower they think it is going. we just love that video. you're watching "fast money" first in business worldwide. here's what else is coming up on "fast." ♪ >> that's what investors in snap want to know as shares continue to fall. but there's one price that could prove a bargain. we'll explain. plus, what are the hottest trades in wall street just starting to unravel? it could

if i'm icahn, i would prefer to be in gilead than bristol meyer. >> they've cured a disease. so i hear you. >> they have a pile of cash and they're not doing anything with it. that's the reason. >> but the other side of the coin is difficult. >> i think these are two names that are very several plays and they're far from excessive. we're back at this holy number. it touched three 1 in, 80 and change today. this is a market call, folks. a total proxy play. >> one they know trump didn't specifically mention is the border adjustment tax. larry kudlow had this to say on squawk alley. >> i am told late yesterday afternoon, might have been early this morning. a meeting of conservative activists with white house representatives, we're told that the white house does in fact favor the border adjustment. the president went to the water's end. didn't quite measure it. through legislative games, they're going to allow votes for and against. but it will be part of deal. >> we saw a slight reaction on those comments. how soon can investors expect to see anything about this? is it too soon

a lot of people felt gilead.he rumor was gilead would buy insight in order to get things going. >> have we confirmed the baker brothers -- >> they filed. >> they filed 34 million shares. credit suisse. >> they're very well-known investors. but i would note they filed something called seattle jen anytimics last october but never sold. just filing to sell doesn't necessarily mean you are selling. >> it's that important. yeah, like chipotle. he filed to sell. >> but is insight down on that news? >> i don't know. it's interesting, invid ya is up. i think that's a statement which says that is the area to be in. not that nvidia is going to be taken over. look, david convinced me, autonomous driving cars are big. i was in one in california. yes, i mean, we're clowns versus the people who run the mind of that car. we're clowns. we inched up to the stop sign. remember studyinging how to do it? everything you study, they do. and they don't drink. autonomous cars, they don't drink. >> they don't text. >> they don't text. th

gilead a value play on biotech, let's do that. news today they got rid of their canadian oil sands property and chesapeake. we will get rid of chesapeake because that is an overlap of conocophillips. is apple and overlap of invidia? yes. we will make it so it's tech and tech, we will handle that. get rid of this and we will buy honeywell! yes. why not? diversified industrial, people criticize me for this. i don't really know what to do. do i tell you to trade apple, the wrong signal. we will give it a track. glen in florida, glen! >> caller: yeah, this is glen from florida. >> hit me, glen, what have you got? >> caller: i have five stocks. general electric, pfizer, vf court and vodafone. >> all right. wow, interesting selection here. it's a yield portfolio. i just love portfolios that have above average yield. pfizer, drug company, higher yield, ge, industrial higher yield, duke energy, one of our absolute favorite yields. i like con ed, but we'll go with duke. vf, higher-year old and vodafone. a utility, industrial and drug compa

you and i go back and forth all the time and i own gilead, it's been painful, but i still believe in their story. they have do something to get the pipeline filled. >> feelslike maybe it would be a great spot for somebody to influence it. >> like a bag holder for the biotech industry? >> are whwhat does that mean? >>. >> the xlv, xbi, etfs, xlv was a really bad false breakout yesterday. above the prior high, above $76 and it could back today. so i'm looking for a move back to $71. >> coming up, the man who moves markets is here. in fact just walking out of the elevator. not only can he move the market, he has great timing, too. he says the stocks are about to give you the money making opportunity of the year. he will explain right after this break. plus media companies which have endured the wrath of president trump could stand to be some of the big winners under the president's plan to try and regulate -- deregulate everything. traders name names next. and it's a battle of the tech titans. will the underdog come through for a big win? more "fast money" right after this. bp uses flir

gilead's for hepatitis c. these are therapies with results for improvements in biology. huge investments in risk-taking by the industry could less about economic district -- economic commission. they continued stream of treatments won't flow if society is not willing to fund and support a modern biopharmaceutical industry. that gets cures to patients. i would like to note that in 2014, the industry in the united states represented 3.8% of total u.s. output. an impact of $1.2 trillion. when you take into account the amount of goods services and the total impact on the economy, $1.2 trillion, this includes the economic activity across the u.s. economy, including supply jobs. i want to be clear, we understand our responsibility. every scientist understands the responsibility. pfizer understands our response ability to produce medicines that bring value and are competitively priced. we are working toward an understanding in our society of the investment we make, the risk we take. and by we, i mean our shareholders. appropriate return on the totality of our investment. a succ

and gilead sciences, $13 billion in profit in 2016 alone. when the cbo released its report last week showing the 24 million hard-working americans would be left without health care coverage by 2026 if we pass this bill, the premiums will rise 15-20% next year. people will pay thousands of dollars more in deductibles and out-of-pocket costs, and older americans will be priced out of the market by an age tax. i thought for sure it was dead on arrival, but there was no way my republican colleagues would walk this plane. -- plank. but here they are, and they are trying to take millions of american families with them. 14 million americans will lose health coverage next year if this bill is approved, trautman million -- 21 million would lose coverage of the next three years alone. wiping out all of the coverage gains from the aca in three years. for pretty much everyone else on the individual market, deductibles and other costs would be higher. for lower income individuals out-of-pocket costs will be much higher. insurance companies will again be

you take, for example the exam of the ibb, gilead is down 20% over the past 12 months, biogen up 14%whole thing is down. how do you defend the etf industry when you can be held hostage to those sorts of effects? >> it's a good comment. jim was talking about the first generation of et frks market indices, you have these massive -- a single name can be as you much as 14% of the portfolio. what i'm talking about is a new generation of product that's now the fourth generation. these are actively managed, so that covenants like a 3% maximum waiting in any one name and multiple tests on the names, themself, they reject high risk nature. that's what's going on here. you can make the argument about first generation etfs that are market cap waited. the eqqs, yes, those are issues, what i'm talking about are brand-new products on the market for as little as 18 months to take away all those risks, so i don't 100% agree with jim on this. >> kevin, good to see you, thank you, kevin o'leary of o shares investments. what is the trade on these robotic movements? >> i don't know. i think the sector e

are other therapy stories like patients with advanced non-small cell cancer and for melanoma and gilead's for hepatitis see. these therapies have huge investment in risk-taking by the industry. let's talk about economic contribution to the industry. a continued stream of new treatments won't flow if society is not willing to fund and support a modern biopharmaceutical industry. that is what gets cures to patients. i would like to note, in 2014 the bio pharmacy industry represented 3.8 of total u.s. output which amounts to an input of one point to trillion dollars. when you take into account the value of goods and services produced by the industry and the total impact on the economy, one point to trillion dollars. this includes the economic activity of the workforce the more than 4.4 million jobs across the u.s. economy including direct and indirect vendor and supply jobs. that being said, i want to be clear, we understand our responsibility. every scientist understands there responsibility and pfizer understands the responsibility to produce medicine that brings significant value and are

gilead science, johnson & johnson was up today, but regeneron pharmaceuticals were also down, they're looking for guidance, not going to get it soon but they're looking at it, liz. liz: we may get guidance soon, i want to keep viewers on notice here. the freedom caucus, according to chad pergram, our super top producer in the congress, he is saying freedom caucus is clustering in one of the halls and will come before the cameras to say what they do not like about it and whether it is, as gerri willis put, it dead on arrival. the freedom caucus is a bloc. stay tuned for that. we've got our cameras chasing everybody. closing bell ringing in 49 minutes. boeing releasing the 747 scheduled to re-enter service in 2018. >>> dish flying higher after it was announced the satellite tv company will replace linear technology corporation in the s&p 500 on march 13th. so dish gets the big invite to be part of the s&p 500. it's up 4.63%. up next, billionaire hedge funder steve cohen side lined by the sec. you remember charlie gasparino said his return to business is starting to look more likely? wel

this is david in texas, and i have a question on gilead.'ve been watching it for a while and it's got a 3% yield, and i'm just wondering if it's time to get in. >> i got to tell you, i mean it's always tempting but they need to make an acquisition. if they came on the show, i'd say without an acquisition, it's just a value trap. i need to go to joyce in texas, joyce. >> caller: hey, jim. i love your show. >> thank you. >> caller: i also love get rich carefully. i have a question. i know earlier this week you did a segment about drugs related to diabetes. and i wonder what you think of novo nor tis. >> we didn't include it because it has very little growth and because the actual -- i mean lilly is a much better growth company than novo. there's a lot of political pressure on novo but not on lilly. let's go to joseph in new york, joseph. >> caller: booyah, jim. >> booyah. >> caller: i wanted to know your thoughts on ticker symbol auth. >> this thing has too much of a move. it's got to call off. i've been watching it. too crazed. let's go to j

pfizer's alcorye, merck's -- [inaudible] for melanoma that and gilead's medicines for hepatitis c. these new therapies are a result of improvements in understanding technology, research with academic and research institutions and huge investment and risk taking by the industry. let's talk about economic contribution to the industry. a continued stream of new treatments won't flow if society is not willing to fund and support a modern bio-pharmaceutical industry that gets cures to patients. i'd like to note that in 2014 the bio-pharmaceutical industry in the united states represented 3.8% of total output which amounts to an impact of more than $1.2 trillion. when you take into account the value of goods and services produced by the industry and the total impact on the economy, $1.2 trillion. this includes the economic activity of its work force and more than 4.4 million jobs across the u.s. economy. including direct and indirect vendor and supply jobs. that being said, i want to be clear: we understand our responsibility. every scientist understands their respondent, everyone as pfi

we want growth from biotech, but gilead is either value or value trap.e want the really great cyber security companies with the really bad cyber security losing to the great ones. makes you think somehow you're diversified, you're not diversified. yes, if you're an etf for gold that may be a better way than owning individual gold stocks, but the brainwashing has to stop. the single stock risk game, that is all about trying to get people to buy certain products that i think are really against their best issues -- their best interests. i got to tell you something, melissa, the people upset about this is typical of how brainwashed people are. listen, i want to buy the bad with the good? oh, wow, i'll fight for that right. >> a lot of great points there, jim, thank you. and of course this is worth watching. look at the clip on cnbc.com, read the article, it's great. see you in a few minutes. later on, don't miss the ceo of winnebago, that's later on "power lunch." but mobility its an autonomous-thinking vehicle protecting those inside and out. and it's the m

for example, gilead sciences reported in 2015 that their tax lower the company's earnings share to $.85 per share. it is highly likely that in order to stay in business and key people hired, they passed costs on to consumers. this tax, along with other taxes and obamacare, need to be repealed. this will put more money in the pockets of americans who need it. older americans who need it. paying for obamacare's phil policies on the backs of seniors was not a solution with law was passed and it has only gotten worse. i fully support repealing these taxes and preserving medicare for future generations. thekfully, because of leadership of this committee over the last six years, we have put solutions in place. solutions that strengthen medicare to make sure it is around for the next generation and not continuing to add to our $20 trillion debt. did we get a better idea from the left when we put these ideas forward the last six years? no, we got tv commercials with a gentleman acting as if he was going to push an elderly citizen off a cliff. that is what the left present is a better idea. need

in fact, gilead said pbms keep prices high. they do this through keeping the prices high so the pbms get a higher rebate. this is one of the problems we have. you're right, the president has made it clear that anyone who's on the other side of r & d needs to be aware, because we're after them, and we're after the pbms, because they are the primary problem here. again, i want to thank you for this. but i'm not sure as dr. burgess has said, i'm not sure this is the right time for us to do it. as the speaker has explained, this is a three-bucket approach that we're trying to get at through health care. this is the first bucket. we've still got those two buckets to go. and at that time, i hope that we can indeed address this. thank you, mr. chairman. i yield back. >> the gentleman's time is expired. the gentle lady from california strikes the last word. >> thank you, mr. chairman. move to strike the last word. very interesting to listen to the chairman of the health subcommittee. and i hope everyone was listening. it was long and w

for example, gilead sciences reported in 2015 that there are $337 million tax lowered the companies earningsrom $2.5 a share to $1.84 a share. it is highly likely that in order to recover that revenue to stay in business, to keep people higher, that they pass these costs along to consumers in the form of higher drug costs. this tax alo with most other taxes in obamacare need to be repealed. this will put more money in the pockets of americans who need it. older americans who need it. paying for obamacare is failed policies on the backs of seniors was not a solution when this law was passed, and it is only gotten worse i totally support repealing this taxes and preserving medicare for future generations. now, thankfully because of the leadership of this committee over the last six years, we have put solutions in place. solutions that strengthen medicare to make sure that it's a rent for the next generation, and not continuing to add to our $20 trillion debt. did we get a better idea from the left when we put these ideas forward for the last six years? no. we got tv commercials. with a lengthy

article about the pbms how they are the primary reasons that drug prices are increasing, and in fact, gilead has said that pbms like that keep the prices high so that the pbms get a higher rebate. this is one of the problems that we v and you are are right, that the president said that anybody on the other side of the r&d needs to be aware and we are after them and the pbms because they are a primary problem here. again, i want thoong you for this, but i am not sure that as dr. burgess has said, it is not the right time to do it as the speaker has explained this is a three-bucket approach that we are trying to get at through health care. this is the first bucket. we have still got the two buckets to go, and at that time, i hope that we can indeed address this. thank you, mr. chairman. i yield back. >> the gentleelman's time has expired. >> and the gentle lady of california and strike the last word. >> thank you, mr. chairman. i move to strike the last word. very interesting to listen to chairman of the health subcommittee. i hope that everyone was listening, because it was long and winding,